Trial · NCT07134088
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
NCT07134088, Phase 1, Phase 2, Active not recruiting, Amgen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia. Trials, record NCT07134088. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07134088
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
- NCT number
- NCT07134088
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 104 participants, estimated
- Lead sponsor
- Amgen
- Conditions
- Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab
- First posted
- 2025-08-21
- Last updated
- 2026-10-05
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 1b: Number of Participants who Experienced Dose Limiting Toxicities (DLTs) | Up to 29 days | |
| Primary | Phase 1b: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs) | Up to approximately 7 months | |
| Primary | Phase 1b: Number of Participants who Experienced Serious TEAEs | Up to 2 years and 7 months | |
| Primary | Phase 1b: Number of Participants who Experienced Treatment-related TEAEs | Up to approximately 7 months | |
| Primary | Phase 1b: Number of Participants who Experienced AEs of Interest (EOI) | Up to approximately 7 months | |
| Primary | Phase 2; R Cohort: Number of Participants who had Complete Remission/Complete Remission with Partial Hematological Recovery (CR/CRh) Within the First 2 Cycles | Up to 70 days | |
| Primary | Phase 2; M Cohort: Number of Participants who had CR with MRD Negative Response Within the First 2 Cycles | Up to 70 days | MRD negative response = MRD level \< 10\^-4 (0.01%). |
| Secondary | Phase 1b: Number of Participants who had CR/CRh Within the First 2 Cycles | Up to 70 days | |
| Secondary | Phase 1b: Number of Participants who had CR Within the First 2 Cycles | Up to 70 days | |
| Secondary | Phase 1b: Number of Participants who had CR/CRh/Complete Remission with Incomplete Hematological Recovery (CRi) or Blast Free Hypoplastic or Aplastic Bone Marrow (BM) Within the First 2 Cycles | Up to 70 days |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07134088
GET https://conductscience.org/api/trials/v1/NCT07134088/registered?page=2